“We co-invented a COVID-19 vaccine candidate with the University of Oxford, which we assigned to Oxford University Innovation, or OUI, to facilitate the license of those rights by OUI to AstraZeneca UK Limited, or AstraZeneca. This vaccine is now known as COVID-19 Vaccine AstraZeneca, which we refer to as AZD1222. AstraZeneca has exclusive worldwide rights to develop and commercialize AZD1222,” the prospectus says.
We are a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer.
We have a broad pipeline of clinical and preclinical therapeutic and prophylactic programs. Our therapeutic programs include VTP-300 to treat chronic hepatitis B infection (CHB); VTP-200 to treat human papilloma virus infection (HPV); VTP-850 to treat prostate cancer, and VTP-600 to treat non-small cell lung cancer (NSCLC). Our prophylactic programs include VTP-400 to prevent herpes zoster, or shingles, and VTP-500 to prevent Middle East respiratory syndrome, or MERS.
(Note: Vaccitech priced its IPO on April 29, 2021, at $17 – the mid-point of its $16-to-$18 range – on 6.5 million shares, the same number of shares as in the prospectus – to raise $110.5 million.)
|Address||Vaccitech plc The Schrödinger Building Heatley Road The Oxford Science Park Oxford OX4 4GE United Kingdom|
|Phone Number||+44 (0) 1865 818 808|
|View Prospectus:||Vaccitech plc|
|Revenues||$4.82 mil (last 12 months)|
|Net Income||$-17.93 mil (last 12 months)|
|Price range||$17.00 - $17.00|
|Est. $ Volume||$110.5 mil|
|Manager / Joint Managers||Morgan Stanley/ Jefferies/ Barclays/ William Blair|
|CO-Managers||H.C. Wainwright & Co.|
|Expected To Trade:||4/30/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|